Current status of genetics research in inflammatory bowel disease

Genes and Immunity

Volumn 6, Issue 8, 2005, Pages 637-645

  Vermeire, Severine ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Genetics; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ALPHA DEFENSIN; AZATHIOPRINE; CORTICOSTEROID; GLUCOCORTICOID; INFLIXIMAB; MURAMYL DIPEPTIDE; RITUXIMAB; STEROID;

ARTHRALGIA; BONE MARROW SUPPRESSION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; ENTERITIS; ENVIRONMENTAL FACTOR; FEVER; GENE IDENTIFICATION; GENE MAPPING; GENE REPLICATION; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MOLECULAR DYNAMICS; MYALGIA; PANCREATITIS; PATHOGENESIS; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REVIEW; THROMBOCYTOPENIA; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

BACTERIA (MICROORGANISMS);

EID: 28544444993     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364257     Document Type: Review

References (114)

1. Roth MP, Petersen GM, McElree C et al. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989; 97: 900-904.
2. Yang H, McElree C, Shanahan F et al. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews. Gut 1993; 34: 517-524.
3. Orholm M, Munkholm P, Langholz E et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-88.
4. Peeters M, Nevens H, Baert F et al. Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111: 597-603.
5. Satsangi J, Rosenberg W, Jewell DP. The prevalence of inflammatory bowel disease in relatives of patients with Crohn's disease. Eur J Gastroenterol Hepatol 1994; 6: 413-416.
6. Laharie D, Debeugny S, Peeters M et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120: 816-819.
7. Tysk C, Lindberg E, Jarnerot G et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-996.
8. Thompson NP, Driscoll R, Pounder RE et al. Genetic versus environment in inflammatory bowel disease: Results of a British Twin Study. BMJ 1996; 312: 95-96.
9. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075-1081.
10. Halfvarson J, Bodin L, Tysk C et al. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124: 1767-1773.
11. Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families. Inflamm Bowel Dis 2001; 7: 8-15.
12. Shanahan F, Duerr R, Rotter JI. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456-461.
13. Bouma G, Crusius JB, Garcia-Gonzalez MA et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999; 115: 294-300.
14. Seibold F, Slametschka D, Gregor M et al. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107: 532-536.
15. Sendid B, Quinton JF, Charrier G et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998; 93: 1306-1310.
16. Landers CJ, Cohavy O, Misra R et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123: 689-699.
17. Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-424.
18. Lodes MJ, Cong Y, Elson CO et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296-1306.
19. The International HapMap Consortium. International HapMap Project. Nature 2003; 426: 789-796.
20. Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821-823.
21. Satsangi J, Parkes M, Louis E et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14: 199-202.
22. Cho JH, Nicolae DL, Gold LH et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998; 95: 7502-7507.
23. Hampe J, Schreiber S, Shaw SH et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999; 64: 808-816.
24. Ma Y, Ohmen JD, Li Z et al. A genome wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-278.
25. Duerr RH, Barmada MM, Zhang L et al. High-Density Genome Scan in Crohn disease Shows Confirmed Linkage to Chromosome 14q11-12. Am J Hum Genet 2000; 66: 1857-1862.
26. Rioux JD, Silverberg MS, Daly MS et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66: 1863-1870.
27. Williams CN, Kocher K, Lander ES, Daly MJ, Rioux JD. Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci. Inflamm Bowel Dis 2002; 8: 375-381.
28. Paavola-Sakki P, Ollikainen V, Helio T et al. Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. Eur J Hum Genet 2003; 11: 112-120.
29. Vermeire S, Rutgeerts P, Van Steen K et al. Genome wide scan in a Flemish inflammatory bowel disease population: Support for the IBD4 locus, population heterogeneity, and epistasis. Gut 2004; 53: 980-986.
30. Barmada MM, Brant SR, Nicolae DL et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004; 10: 15-22.
31. van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM. Genome Scan Meta-Analysis Group of the IBD International Genetics Consortium Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004; 13: 763-770.
32. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
33. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
34. Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-1928.
35. Lesage S, Zouali H, Cezard JP et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-857.
36. Rosenstiel P, Fantini M, Brautigam K et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124: 1001-1009.
37. Lala S, Ogura Y, Osborne C et al. Crohn's disease and the NOD2 gene: A role for paneth cells. Gastroenterology 2003; 125: 47-57.
38. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993-1000.
39. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/ Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-4818.
40. Gutierrez O, Pipaon C, Inohara N et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002; 277: 41701-41705.
41. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509-5512.
42. Kobayashi KS, Chamaillard M, Ogura Yet al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.
43. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1658-1664.
44. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800-808.
45. Maeda S, Hsu LC, Liu H et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307: 734-738.
46. Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004; 36: 476-480.
47. Daly MJ, Pearce AV, Farwell L et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet 2005; 13: 835-839.
48. Noble CL, Nimmo ER, Drummond H et al. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 2005; Apr 20 (Epub ahead of print).
49. Torok HP, Glas J, Tonenchi L et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 2005; Jun 14 (Epub ahead of print).
50. Vermeire S, Pierik M, Henckaerts L et al. Study on DLG5 and OCTN polymorphisms shows association of the OCTN TC risk haplotype with perianal and fistulizing Crohn's disease but not with susceptibility to IBD. Gastroenterol, in press.
51. Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36: 471-475.
52. Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29: 223-228.
53. Giallourakis C, Stoll M, Miller K et al. IBD5 is a general risk Factor for inflammatory bowel disease: Replication of association with Crohn's disease and identification of a novel association with ulcerative colitis? Am J Hum Genet 2003; 73: 205-211.
54. Negoro K, McGovern DPB, Kinouchi Y et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut 2003; 52: 541-546.
55. Mirza MM, Fisher SA, King K et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn disease. Am J Hum Genet 2003; 72: 1018-1022.
56. Mc Govern DPB, van Heel DA, Negoro K et al. Further evidence of IBD5/ CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitis. Am J Hum Genet 2003; 73: 1465-1466.
57. Gründemann D, Gorboulev V, Gambaryan S et al. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549-552.
58. Lahjouji K, Mitchell GA, Qureshi IA. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab 2001; 73: 287-297.
59. Tamai I, Yabuuchi H, Nezu J et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 1997; 419: 107-111.
60. Wu X, Prasad PD, Leibach FH et al. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 1998; 246: 589-595.
61. Roediger WE, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp 1986; 67: 773-782.
62. McGovern DP, Hysi P, Ahmad T et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005; 14: 1245-1250.
63. Zouali H, Lesage S, Merlin F et al. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003; 52: 71-74.
64. Toyoda H, Wang SJ, Yang HY et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104: 741-748.
65. Danze PM, Colombel JF, Jacquot S et al. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 1996; 39: 69-72.
66. Satsangi J, Welsh KI, Bunce M et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-1217.
67. Stokkers PC, Reitsma PH, Tytgat GN et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: A meta-analysis. Gut 1999; 45: 395-401.
68. Franchimont D, Vermeire S, El Housni H et al. Deficient hostbacteria interactions in inflammatory bowel disease. The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-992.
69. Lakatos PL, Lakatos L, Szalay F et al, Hungarian IBD Study Group. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations. World J Gastroenterol 2005; 11: 1489-1495.
70. Gazouli M, Mantzaris G, Kotsinas A et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11: 681-685.
71. Torok HP, Glas J, Tonenchi L et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112: 85-91.
72. Oostenbrug LE, Drenth JP, de Jong DJ et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 567-575.
73. Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-688.
74. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854-866.
75. Cavanaugh JA, Adams KE, Quak EJ et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 2003; 67: 35-41.
76. Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867-874.
77. Esters N, Pierik M, van Steen K et al. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 299-305.
78. Mendoza JL, Murillo LS, Fernandez L et al. Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn disease. Scand J Gastroenterol 2003; 38: 1235-1240.
79. Roussomoustakaki M, Koutroubakis I, Vardas EM et al. NOD2 insertion mutation in a Cretan Crohn's disease population. Gastroenterology 2003; 124: 272-273.
80. Vermeire S, Wild G, Kocher K et al. CARD15 genetic variation in a Quebec population: Prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71: 74-83.
81. Helio T, Halme L, Lappalainen M et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003; 52: 558-562.
82. Bairead E, Harmon DL, Curtis AM et al. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet 2003; 11: 237-244.
83. Arnott ID, Nimmo ER, Drummond HE et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: Evidence for genetic heterogeneity within Europe? Genes Immun 2004; 5: 417-425.
84. Inoue N, Tamura K, Kinouchi Y et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123: 86-91.
85. Sugimura M, Kinouchi Y, Takahashi S et al. CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. Clin Genet 2003; 63: 160-162.
86. Leong RWL, Armuzzi A, Ahmad Tet al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 2003; 17: 1465-1470.
87. Bonen DK, Niclolae DL, Moran T et al. Racial differences in Nod2 variation: Characterization of Nod2 in African-Americans with Crohn's disease. Gastroenterology 2002; 122 (Suppl): A-29.
88. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: A Cohort Study. Lancet 2002; 359: 1661-1665.
89. Holler E, Rogler G, Herfarth H et al. Both donor and recipient NOD2/ CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-894.
90. Armuzzi A, Ahmad T, Ling KL et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003; 52: 1133-1139.
91. Libioulle C, Thys J, Farnir F et al. Functional variants of Octn cation transporter gene are associated with perianal Crohn's disease. Gastroenterol Suppl 2005; 128: A445.
92. Newman B, Gu X,Wintle R et al. A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 2005; 128: 260-269.
93. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-1853.
94. Orchard TR, Thiyagaraja S, Welsh KI et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-278.
95. Orchard TR, Chua CN, Ahmad T et al. Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-718.
96. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history. Gut 1998; 42: 387-391.
97. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
98. Farrell RJ, Murphy A, Long A et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279-288.
99. Honda M, Orii F, Ayabe T et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118: 859-866.
100. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
101. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614.
102. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713.
103. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-646.
104. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030.
105. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915.
106. Louis E, Vermeire S, Rutgeerts P et al. A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824.
107. Mascheretti S, Hampe J, Kuhbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenom J 2002; 2: 127-136.
108. Pierik M, Vermeire S, Van Steen K et al. TNF-Alpha receptor 1 and 2 (TNFR1 and TNFR2) polymorphisms in IBD and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303-310.
109. Vermeire S, Louis E, Rutgeerts P et al Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106-111.
110. Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: An analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-515.
111. Louis E, El Ghoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-519.
112. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
113. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002; 99: 754-758.
114. Hlavaty T, Pierik M, Joossens S et al. Genotype TT in the promoter region of apoptotic gene Fas ligand is associated with unfavorable clinical response to infliximab treatment in refractory luminal Crohn's disease. Aliment Pharmacol Ther (in press).